Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
On February 2, 2024, Catalent and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, announced a merger agreement under which Novo Holdings will acquire Catalent, Inc. According to the news release, Catalent’s board of directors approved the merger agreement for $63.50 per share in cash. The deal is valued at approximately $16.5 billion and is expected to close towards the end of 2024.
Robbins LLP is concerned that Catalent’s board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.
Next Steps: If you own shares of Catalent, Inc. (CLTL) you have legal options. Contact us to learn more about your legal rights.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
